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Sialuria is an inborn error of metabolism characterized by coarse face, hepatomegaly and recurrent respiratory tract infections. The genetic
defect in this disorder results in a loss of feedback control of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine-kinase by CMP-N-
acetylneuraminic acid (CMP-NeuAc) resulting in a substantial overproduction of cytoplasmic free sialic acid. This study addresses fibroblast
CMP-NeuAc levels and N- and O-glycan sialylation of serum proteins from Sialuria patients. CMP-NeuAc levels were measured with HPLC in
fibroblasts. Isoelectric focusing (IEF) of serum transferrin and of apolipoprotein C-III (apoC-III) was performed on serum of three Sialuria
patients. Isoforms of these proteins can be used as specific markers for the biosynthesis of N- and core 1 O-glycans. Furthermore, total N- and O-
linked glycans from serum proteins were analyzed by HPLC. HPLC showed a clear overproduction of CMP-NeuAc in fibroblasts of a Sialuria
patient. Minor changes were found for serum N-glycans and hypersialylation was found for core 1 O-glycans on serum apoC-III and on total
serum O-glycans in Sialuria patients. HPLC showed an increased ratio of disialylated over monosialylated core 1 O-glycans. The hypersialylation
of core 1 O-glycans is due to the increase of NeuAcα2,6-containing structures (mainly NeuAcα2-3Galβ1-3[NeuAcα2-6]GalNAc). This may
relate to KM differences between GalNAc-α2,6-sialyltransferase and α2,3-sialyltransferases. This is the first study demonstrating that the genetic
defect in Sialuria results in a CMP-NeuAc overproduction. Subsequently, increased amounts of α2,6-linked NeuAc were found on serum core 1
O-glycans from Sialuria patients. N-glycosylation of serum proteins seems largely unaffected. Sialuria is the first metabolic disorder presenting
with hypersialylated O-glycans.
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Sialuria (OMIM 269921), formerly called French type
Sialuria, is an autosomal dominant inborn error of metabolism
in which the feedback control mechanism in the biosynthesis of
cytidine-monophosphate-N-acetylneuraminic acid (CMP-
NeuAc) is lost. This is caused by a defect in the gene coding
for the enzyme uridine diphosphate-N-acetylglucosamine-2-
epimerase/N-acetylmannosamine kinase (GNE/MNK, EC
5.1.3.14) [1,2]. Heterozygous mutations in the region of codons
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the rate-limiting enzyme in the biosynthesis of CMP-NeuAc. It
is a bifunctional enzyme that catalyzes the first two biosynthetic
steps of CMP-NeuAc formation. These are the epimerization of
UDP-N-acetylglucosamine (UDP-GlcNAc) to N-acetylmanno-
samine (ManNAc) and the phosphorylation of ManNAc to
ManNAc-6-phosphate by the kinase part of the enzyme [4]. The
epimerase and the kinase domain work independently of each
other [5]. The epimerization is feedback-inhibited by CMP-
NeuAc, the end product of the pathway. [6,7]. The lack of
feedback inhibition of GNE/MNK results in an extreme
overproduction of free sialic acid in the cytoplasm [8]. To
date, seven patients have been reported with Sialuria presenting
clinical features that include mild psychomotor delay, coarse
facies, recurrent upper respiratory tract infections and hepato-
megaly [3,9–13]. The pathophysiology of the disease is poorly
understood.
The presence of sialic acid on glycans is crucial for their
function in numerous physiological processes including cell
recognition and adhesion, cell migration and antigenicity [14].
The congenital disorders of glycosylation (CDG) form a group
of autosomal recessive metabolic disorders caused by defects in
the biosynthesis of protein-linked glycans. The glycoproteins of
CDG patients often show hypoglycosylation. This group of
disorders has shown that changes in the glycan structure may
lead to severe multisystem disease [15,16]. Transferrin
isofocusing on serum is generally used in the screening to
diagnose patients suffering from a defect in the N-glycan
biosynthesis [17]. Apolipoprotein C-III isofocusing can be used
as a screening method for defects in the biosynthesis of core 1
O-glycans [18]. The core 1 O-glycan, which has Galβ1-
3GalNAc-Ser/Thr as the core, is the most common O-linked
glycan type and occurs on many membrane and secreted
proteins.
In the current study, we analyzed nucleotide sugar levels in
fibroblasts with HPLC to study CMP-NeuAc levels in a
Sialuria patient. Subsequently, apoC-III IEF, transferrin IEF
and HPLC of total serum protein glycans were used to
investigate serum protein glycosylation in Sialuria patients. It
was shown that CMP-NeuAc levels were clearly increased in a
Sialuria patient. Furthermore, these patients were shown to
have hypersialylated O-glycans due to increased levels of α2,6-
linked NeuAc in core 1 O-glycans. These findings offer a new
perspective for studying Sialuria pathogenesis. To our
knowledge, this is the first report that shows an overproduction
of CMP-NeuAc in Sialuria, which results in increased protein
O-glycan sialylation. This is also the first time that hypersia-
lylation of serum proteins is demonstrated in an inborn error of
metabolism.
2. Patients and methods
2.1. Patients
A unique feature in Sialuria is a relatively benign clinical course with a
significant improvement in adulthood. Blood samples from patients A, patient 1
in [3], B, patient 2 in [3]; and C, the patient described in [10,19] have been used
for the current study. Patient B is the mother of patient A. Only a slight mentaldelay is reported in the mother. Patient B and her son, patient A, carry the same
heterozygous R266Q mutation in the GNE/MNK gene [3].
2.2. Samples and sample preparation
A skin biopsy was obtained from patient C and blood samples were obtained
from Sialuria patients A, B and C with informed parental consent. Serum was
prepared by centrifugation and stored immediately at −80 °C until required for
analysis. Fibroblasts used for the reference range of nucleotide sugar analysis
were obtained from 7 healthy controls after written informed consent.
2.3. HPLC of nucleotide sugars
Analysis of nucleotide sugars with HPLC was carried out essentially as
described by Räbina et al. [20]. Fibroblasts were cultured in medium 199 (cat.
no. 041-94259; Gibco) containing 10% fetal calf serum and 1% Penicillin–
Streptomycin at 37 °C. The fibroblast cells (between 10×106 and 20×106 cells)
were harvested by trypsinization and washed 4 times with PBS. The pellet was
stored in −20 °C until further use. The pellet was resuspended in 600 μl 20 mM
NH4HCO3 (pH 10.6) and sonicated for 6×8 s on ice. After sonication, 600 μl
of 2 M NH4HCO3 (pH 7) was added and the sample was applied to an Envi-
Carb carbon column (Supelco) for the isolation of the nucleotide sugars
according to the method of Räbina et al. [20] with minor modifications. Prior to
use, the Envi-Carb carbon column was conditioned with 3 ml 80% (v/v)
acetonitrile in 0.1% (v/v) trifluoroacetic acid, followed by 2 ml of water. The
sample was subsequently applied to the column and washed with 2 ml water,
2 ml 25% (v/v) acetonitrile, and 2 ml 50 mM triethylammonium acetate buffer
(TEAA buffer) (pH 6.7). Nucleotide sugars were then eluted with 2 ml 25%
(v/v) acetonitrile containing 50 TEAA buffer (pH 6.7), dried in a vacuum
centrifuge and stored at –20 °C until further use. The sample was redissolved
in 600 μl 20 mM TEAA buffer (pH 4.0) and 250 μl sample was injected on
a Discovery C18 column (0.46×25 cm; Supelco). Nucleotide sugars were
eluted isocratically with 20 mM TEAA buffer (pH 4.0) at a flow rate of
1 ml/min. The reference mixture contained 1 μM CMP-NeuAc, tyrosine,
UDP-Gal, UDP-Glc, GDP-Man, and UDP-GalNAc (Sigma Aldrich). The
effluent was monitored with a UV detector (Applied Biosystem, nr. 785 A) at
255 nm and the nucleotide sugars were quantified with PC1000 software
(Spectra-Physics).
2.4. Isoelectric focusing (IEF) of serum glycoproteins
2.4.1. Transferrin
TIEF was carried out essentially as described by van Eijk and van Noort
[21]. Serum samples were incubated for 30 min with 20 mM ferric citrate and
0.5 mM sodium hydrogen carbonate in a ratio of 10:3 (serum to solution) to
saturate the transferrin with iron. The iron-saturated serum was diluted 5 times
with water and 1 μl was applied to a hydrated dry Phastgel (2.5% ampholines pH
5–7 solution) on a PhastSystem (Amersham Pharmacia Biotech). After IEF, the
transferrin isoforms were detected by adding rabbit anti-human transferrin
antibody (Dako, Glostrup, Denmark) and the gels were stained with Coomassie
blue. The relative amounts of the transferrin isoforms were determined by
scanning the stained gel using an Image master Labscan, Ver. 3.00 and
quantified using Image master 1D gel analysis, Ver. 4.10, software (Amersham
Pharmacia Biotech).
2.4.2. Apolipoprotein C-III
IEF of apoC-III was carried out as described by Wopereis et al. [18]. A dry
IEF Phastgel was hydrated in a solution of 8M urea and 60 mL/L Pharmalyte pH
4.2–4.9 (cat. no. 17-0560-01; Amersham Pharmacia Biotech) and Ampholine
pH 3.5–5.0 (cat. no. 80-1125-89; Amersham Pharmacia Biotech) in a ratio of
2:1. Serum samples were diluted 10-fold with saline and applied to the hydrated
gel on a Phastsystem (Amersham Pharmacia Biotech). After IEF the isoforms of
apoC-III were detected by Western blotting using rabbit anti-human apoC-III
antibody (ANAWA Biomedical Services and Products) and goat anti-rabbit
horseradish peroxidase-coupled antibody as the secondary antibody and
visualized by electrochemiluminescence. The relative amounts of the apoC-III
isoforms were determined by densitometry as described above.
Table 1
Relative percentages of nucleotide sugars presented as percentage of total














1 CMP-NeuAc 5.8 3–12 70
2 Tyrosine 6.0 – –
3 UDP-Gal 8.8 12–38 27




6 GDP-Man 12.5 5–24 1
Amounts of each nucleotide sugar presented as percentage of total nucleotide
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serum proteins
The total N-linked glycans were released enzymatically from serum proteins
by PNGaseF (Roche Applied Sciences) digestion. Hydrazine release of O-
glycans was carried out as described by Royle et al. [22]. Glycans were
fluorescently labeled using 2-aminobenzamide (2AB) by reductive amination
according to the method of Bigge et al. [23] using an LudgerTag 2-AB labeling
kit (Ludger Ltd., Oxford, UK). NP-HPLC was performed on a TSK Amide-80
250×4.6 mm column (Anachem, Luthon, UK) according to the low-salt buffer
system described by Guile et al. [24]. The HPLC system was calibrated using an
external standard of 2-AB labeled glucose oligomers. Retention times were
converted to glucose units (GU) by comparison to the standard glucose oligomer
ladder using a fifth order polynomal fit. Structures were allocated by matching
experimental GU values obtained from exoglycosidase enzymes arrays and
MALDI mass spectrometry with standard values in a database [22]. This
database is publically available.sugars (peaks 1+3–6=100%). The reference values for nucleotide sugars are
from 7 healthy volunteers. The corresponding RP-HPLC chromatogram is
shown in Fig. 1.3. Results
3.1. Separation and quantification of nucleotide sugars by
HPLC
In Fig. 1, the HPLC chromatograms are shown of fibroblast
nucleotide sugars of a control and Sialuria patient C. A standard
run shows the positions of the different nucleotide sugars in the
chromatogram. The relative amounts of the nucleotide sugars
are listed in Table 1. The relative amount of CMP-NeuAc (peak
1) is approximately 5 times the upper reference range in
Sialuria patient C, whereas the amounts of UDP-Glc (peak 4),Fig. 1. RP-HPLC profiles of nucleotide sugar analyses of control versus Sialuria
patient C. The standard shows the retention times of the different nucleotide
sugars. The relative amounts and the corresponding structures of the peaks are
listed in Table 1.UDP-HexNAc (peak 5) and GDP-Man (peak 6) are clearly
decreased.
3.2. Isoelectric focusing (IEF) of serum glycoproteins
3.2.1. IEF of serum transferrin
In the three Sialuria patients, a slight hypersialylation profile
was found for serum transferrin (Fig. 2, lanes 1–4). The relative
amounts of the transferrin isoforms of the three patients with
Sialuria are summarized in Table 2A. Patient A had increased
relative amounts of hexa- and heptasialo transferrin and in
patients B and C, the heptasialo transferrin isoform was only
very slightly increased. Polymorphisms in the amino acid
sequence changing the isoelectric point of transferrin isoforms
(thus causing an abnormal TIEF profile) were excluded by
incubation of the samples with sialidase [25]. This removes the
negatively charged terminal sialic acid residues. After sialidase
treatment all transferrin isoforms migrated to the asialo position,
indicating that changes in sialic acid content had been
responsible for the abnormal profiles (data not shown).
3.2.2. IEF of serum apoC-III
In all three Sialuria patients, a clear hypersialylation profile
was found for serum apoC-III (Fig. 2, lanes 5–8 and Table 2B).
The three apoC-III isoforms, apoC-III0, apoC-III1 and apoC-
III2, correspond to the asialo, the monosialo and disialo fraction
of the protein respectively. The apoC-III profiles showed an
increase of the relative proportions of apoC-III2 and a decrease
of the relative amount of apoC-III1 in all three patients.
Polymorphisms in the amino acid sequence changing the
isoelectric point of apoC-III isoforms (thus causing an abnormal
apoC-III profile) were excluded by incubation of the samples
with sialidase to remove the negatively charged terminal sialic
acid residues [18]. After sialidase treatment all apoC-III
isoforms migrated to the apoC-III0 position, indicating that
changes in sialic acid content had been responsible for the
abnormal profiles (data not shown).
Fig. 2. Isoelectric focusing profiles of serum transferrin (lane 1–4) and apoC-III (lane 5–9). Lanes 1 and 5: Control, Lanes 2 and 6: Patient A, Lanes 3 and 7: patient B,
Lanes 4 and 8: Patient C, Lane 9: sialidase-treated sample from patient A, 0–7 in the TIEF profiles corresponds with the number of terminal sialic acid residues on the
N-glycans of transferrin. 0–2 in the apoC-III profile correspond with the number of terminal sialic acid residues on the core 1 O-glycan on apoC-III. The relative
amounts of the bands are listed in Tables 2A and B.
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3.3.1. N-glycans
In Fig. 3A, the normal phase HPLC (NP-HPLC)
chromatograms are shown of total serum N-glycans for a
control versus the three Sialuria patients. Peaks 1–10 are
neutral N-glycans lacking terminal sialic acid residues. Peaks
11–22 correspond to sialic acid containing N-glycans. No
increase was observed in the total sialylation level of N-
linked glycans in serum of the three Sialuria patients. The
relative amounts and the corresponding structures of the
peaks detected with NP-HPLC are listed in Table 3A. There
were some differences in relative amounts of some of the
individual N-glycan structures in comparison to controls.
Patients A and B for example showed increased amounts of
the fully sialylated biantennary N-glycan structure (peak 16),
while patient C had an increase of the fully sialylated
fucosylated biantennary N-glycan structure (peak 17). For all
three Sialuria patients, however, the relative amounts of total
fully sialylated biantennary N-glycan structures were within
the control range.Table 2A
Relative amounts of transferrin isoforms presented as percentage of total
transferrin
Transferrin Reference interval (n=28) Patients
Mean (SD) Range A B C
T0 1 (2) 0–3 0 0 0
T1 1 (2) 0–6 0 0 3
T2 6 (2) 2–10 4 5 6
T3 9 (3) 3–14 7 11 13
T4 54 (13) 44–68 44 49 48
T5 21 (4) 15–27 24 26 21
T6 5 (2) 3–12 15 8 8
T7 0 (0) 0 6 1 1
T Transferrin
0 to 7 Number of terminal sialic acid
The corresponding TIEF profiles are shown in Fig. 2 (lanes 1–4). There is no
difference in the reference interval between adults and children.3.3.2. O-glycans
In Fig. 3B, the NP-HPLC chromatograms of total serum O-
glycans are shown for a control and for the three Sialuria
patients. A blank run shows the contamination peak at the
position of the asialo core 1 O-glycan (Galβ1-3GalNAc). This
contamination peak is consistent in all samples and accounts
maximally for about 20% of peak 1. The relative amounts and
the corresponding structures of the peaks detected with NP-
HPLC are listed in Table 3B. Peak 2 (NeuAcα2-3Gal) is the
peeling product induced by the O-glycan hydrazinolysis. In the
ten controls, the monosialylated fractions (peaks 2, 3 and 4)
accounted for the majority of the O-glycans with a mean
percentage of 74.2% of total O-glycans; the disialo core 1 O-
glycan (peak 5) is 13.2% of total O-glycans, while only small
amounts of Galβ1-3[NeuAcα2-6]GalNAc (peak 4) and dis-
ialylated core 2 O-glycan (peak 6) were detected. In the three
Sialuria patients, the relative amounts of the disialylated core 1
O-glycan (peak 5) is clearly increased, while the relative
amounts of the monosialylated core 1 O-glycans (peak 2+3+4)
are decreased with 8.5–11.5% in the three Sialuria patients. This
results in a ratio disialylated / monosialylated core 1 O-glycans
of approximately 1.5–1.9 times the upper reference range in the
three Sialuria patients and corresponds to the hypersialylation
that we found by apoC-III IEF. A more closer look at the relative
values of the individual monosialylated structures shows clearly
that peak 3 is decreased in patients A and B, while peak 4 withTable 2B
Relative amounts of apoC-III isoforms presented as percentage of total apoC-III
ApoC-III Reference intervals Patients
Children (n=30) Adults (n=30) A B C
Mean (SD) Range Mean (SD) Range Child Adult Adult
ApoC-III0 5.1 (2.7) 0–12 8.5 (4.1) 3–19 3 4 1
ApoC-III1 53.2 (9.1) 33–67 55.5 (6.5) 43–69 19 24 36
ApoC-III2 41.6 (8.3) 27–60 36.0 (7.2) 23–50 78 72 63
ApoC-III0, apoC-III1 and apoC-III2 correspond to the asialo, monosialo and
disialo fraction of the protein, respectively. The corresponding apoC-III IEF
profiles are shown in Fig. 2 (lanes 5–8).
Fig. 3. (A) NP-HPLC profiles of total serum N-glycans of control versus Sialuria patients A, B and C. The relative amounts and the corresponding structures of the
peaks are listed in Table 3A. (B) NP-HPLC profile of total serum O-glycans of control versus Sialuria patients A, B and C. The blank run shows a small contamination
peak (peak assigned with *1) with similar retention time as peak 1 in total serum chromatograms. The relative amounts and the corresponding structures of the peaks
are listed in Table 3B. *2 represents an aspecific peak.
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Sialuria patients. This suggests that an increased α2,6-
sialylation mainly causes the increase of the disialylated core
1 O-glycan. The relative amounts of the asialo core 1 O-glycan
seem to be at about the same level in the Sialuria patients.Table 3A
Summary of the relative percentages of sialylated N-linked glycans from total serum4. Discussion
Sialuria patients have an increased sialylation of the core 1
O-glycan on serum apolipoprotein C-III. Increased sialylation
was also found for total serum O-glycans after hydrazinolysis.proteins detected by NP-HPLC
(continued on next page)
Table 3A (continued)
Amounts of each N-glycan presented as percentage of total N-linked glycans (peaks 1–22=100%). The reference values for total serum N-glycans are from
10 healthy volunteers (adults and children). The corresponding NP-HPLC chromatogram is shown in Fig. 3A.
Name abbreviations: all N-glycans have two core GlcNAcs and three Man; Fc, core fucose linked α 1–6 to inner GlcNAc; Ax, number of antenna on core;
B, bisecting GlcNAc linked β 1–4 to inner mannose; Gx, number of galactose on antenna; Sx, number of sialic acids on antenna; GU, glucose units.
Symbols: ■ GlcNAc; ○ Man; ◊ Ga:★NeuNac; Fuc.
⁎ These are presumed structures. Exoglycosidase digestions did not fully confirm these structures.
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metabolism may be readily explained by increased intracellu-
lar CMP-NeuAc levels. The bifunctional enzyme GNE/MNK,
defective in Sialuria, is the rate-limiting enzyme of CMP-
NeuAc biosynthesis. CMP-NeuAc is formed from NeuAc. An
enormous overproduction of NeuAc is the biochemical
hallmark of the disease. It is therefore conceivable that this
will result in increased amounts of intracellular CMP-NeuAc,
the donor substrate for the sialylation of glycans. Our studyshows that the relative amount of CMP-NeuAc was indeed
clearly increased in fibroblasts of patient C. CMP-NeuAc is
synthesized in the nucleus from cytosolic NeuAc. It enters the
lumen of the Golgi via specific antiporters. Inside the Golgi,
specific sialyltransferases use CMP-NeuAc to attachNeuAc at the
termini of N- and O-glycans [26,27]. Our data show a clear
hypersialylation of O-glycans, but only minor changes on N-
glycans. For apoC-III, which carries a core 1 O-glycan, the
disialylated apoC-III2 amounted to 63 and 72% in the Sialuria
Table 3B
Summary of the relative percentages of O-linked glycans from total serum proteins and detected by NP-HPLC
Amounts of each O-glycan presented as percentage of total O-linked glycans. The reference values for total serum O-glycans are from 10 healthy volunteers
(adults and children). Structures were assigned by reference to a GU database [22] in conjunction with a range of exoglycosidase digestions. The corresponding
NP-HPLC chromatogram is shown in Fig. 3B.
Symbols: O GAlNAc; ◊ Gal;★ NeuAc; ■ GlcNac.
1 This peak also contains about 20% background contamination (see bottom panel of Fig. 3B).
2 Small amounts of monosialylated core 2 will be obscured by this large peak of disialylated core 1.
3 This patient is a child.
4 This patient is an adult.
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for 23–50% in healthy adults and for 27–60% in healthy children,
respectively. The analysis of total serum O-glycans showed a
similar overrepresentation of disialylated core 1 O-glycans with a
clearly abnormal ratio of disialylated over monosialylated core 1
O-glycans. Especially, the amounts of core 1 O-glycans carrying
the α2,6-bound NeuAc were clearly increased.
The pathogenesis of Sialuria is largely unknown. Until this
study, the only biochemical abnormalities detected have been the
extremely high levels of free sialic acid in the cytoplasm of cells
and in urine. CMP-NeuAc levels were found to be normal as
analyzed by Seppala et al. [1] and Thomas et al. [28]. Analysis of
total protein-bound sialic acid levels were determined before by
Seppala et al. and Thomas et al. [1,28] and were then found to be
normal. Our study now indicates an increase of CMP-NeuAc
levels in an assay for detecting isolated nucleotide sugars and a
specific increase of α2,6-linked NeuAc residues in serum
protein-linked O-glycans. In previous studies these subtle effects
could have been overlooked since only total protein sialylation
was investigated. The total effect of the increase in protein O-
glycan sialylation, however, is not as pronounced as the increaseof free NeuAc. Seemingly, the biosynthesis of core 1 O-glycans
and specifically of N-glycans is highly controlled. The
biosynthesis routing from free NeuAc to bound NeuAc involves
many steps. Firstly, NeuAc has to be converted to CMP-NeuAc,
subsequently CMP-NeuAc has to be transported to the Golgi by
a specific CMP-NeuAc transporter with a probable limited
transport rate and finally specific sialyltransferases with their
own KM have to attach the sialic acid residue to the protein.
Subsequently, the CMP-NeuAc transporter is an antiporter,
which means that CMP-NeuAc import into the Golgi is coupled
to the equimolar export of CMP-residues. Because CMP is an
inhibitor for sialyltransferases, the sialylation rate itself also has
an influence on the influx of CMP-NeuAc and consequently on
the concentration of this substrate in the Golgi [29].
The genetic defect in Sialuria mainly influences the
incorporation of NeuAc in core 1 O-glycans and not so much
into N-glycans. The opposite has been observed before in
another inborn error in this pathway. A decrease in CMP-NeuAc
biosynthesis in hereditary inclusion body myopathy (hIBM,
OMIM 600737) leads to hyposialylated core 1 O-glycans, while
also the sialylation level of N-glycans is seemingly unaffected
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in relation to cancer, due to the increase of both α2,3- and α2,6-
linked sialic acid residues [31]. To our knowledge, Sialuria is
the first example of an inborn error of metabolism resulting in
the hypersialylation of serum O-linked glycans.
The specific increase in core 1 O-glycan α2,6-sialylation and
not in core 1 O-glycan α2,3-sialylation or in N-glycan
sialylation, may relate to individual KM for CMP-NeuAc of
sialyltransferases. The human sialyltransferase family consists
of at least 15 members. So far, three members of the human
GalNAc-α2,6-sialyltransferases (ST6GalNAc I, II and IV) have
been cloned and characterized. These transferases specifically
catalyze the formation of α2,6-linkages onto GalNAc residues
in mucin type O-glycans. Human ST6GalNAc I exhibits the
broadest specificity reacting with the Tn- and T-antigens and the
α2,3-sialylated core 1 O-glycan. ST6GalNAc II only acts on the
T-antigen and α2,3-sialylated core 1 O-glycan, whereas
ST6GalNAc IV activity is restricted to α2,3-sialylated core 1
O-glycan as substrate. ST6GalNAc II and ST6GalNAc IV are
known to be expressed in many tissues including the liver,
whereas for ST6GalNAc I, the tissue expression has not been
examined [26]. The Gal-α2,3-sialyltransferases (ST3Gal trans-
ferases) in the liver act specifically on type 1 (Galβ1-3GalNAc)
or type 2 (Galβ1-4GlcNAc) epitopes. Thus, it is unlikely that
the ST3Gal transferases involved in serum protein N-glycan
sialylation are involved in α2,3-sialylation of serum protein
core 1 O-glycans [26]. So, different sialyltransferases are
responsible for N-glycan sialylation, O-glycan α2,3-sialylation
and O-glycan α2,6-sialylation. It is known that the two
ST6GalNAc transferases in liver tissue have a nearly 10-fold
higher KM value for CMP-NeuAc than the ST3Gal I [32–34].
This higher KM could be the explanation for the increased α2,6-
sialylation in Sialuria.
The number of acceptor sites available for α2,6-sialic acid
compared to the number of acceptor sites available for α2,3-
sialic acid could also be an explanation for the specific increase
of α2,6-sialylation. For O-glycans, most acceptor sites are
available for α2,6 sialylation (i.e. structure 3 is most abundant,
Table 3B). However, if α2,3-sialylation would be increased, a
decrease would be expected of the asialo core 1 O-glycan
(structure 1, Table 3B). Subsequently, despite the fact that
roughly 50% of the N-glycan structures have one or more
NeuAc acceptor sites, no increase in total sialylation is
observed. The decrease of the α2,3-monosialylated core 1 O-
glycan (structure 3, Table 3B) and the increase of the α2,6-
monosialylated core 1 O-glycan (structure 4, Table 3B) also
suggest a specific increase of O-glycan α2,6-sialylation.
Another possible explanation for the differential influence of
the Sialuria defect on N-glycan and O-glycan sialylation may
derive from differences in the transport of CMP-NeuAc to the
Golgi. The Golgi localization of N-glycan sialyltransferases
differs from the localization of core 1 O-glycan sialyltrans-
ferases. The N-glycan sialyltransferases are localized in the
trans Golgi network (TGN), while the core 1 O-glycan
sialyltransferases are distributed in a separate Golgi compart-
ment proximal to the TGN [35]. It is not known how CMP-
NeuAc is delivered to the sites where sialylation occurs. Thedifferent Golgi compartments may share the same CMP-NeuAc
transporter that functions differently in the distinct compart-
ments. Alternatively, the different Golgi compartments could
have specific CMP-NeuAc transporters. Both models could
help to explain the different susceptibility of N- and O-glycan
biosynthesis for decreased CMP-NeuAc levels (as seen in
hIBM; [36]) and for increased CMP-NeuAc levels as seems to
be the case in Sialuria. Separate CMP-NeuAc transporters for
the different Golgi compartments would also explain the normal
serum N-glycan sialylation levels and abnormal sialylated core
1 O-glycan levels observed in plasma from CDG-IIf patients
who have a deficient CMP-NeuAc transporter [37].
We prefer the ‘affinity model’ as it can explain both the
difference between N- and core 1 O-glycan sialylation as well as
the increased amounts of α2,6-linked NeuAc residues in O-
glycans observed in serum of the three Sialuria patients.
Subsequently, only one CMP-NeuAc transporter has been
described to date and no literature is known that describes a
nucleotide sugar transporter that functions differentially in
distinct locations.
In summary, the genetic defect in Sialuria results in an
overproduction of free cytoplasmic NeuAc and may also result
in an overproduction of cytoplasmic CMP-NeuAc shown in
fibroblasts of patient C. The genetic defect led to increasedα2,6-
linked NeuAc in serum core 1 O-glycans, whereas the sialylation
of N-glycans only showed minor changes. The reported
abnormalities may offer a new perspective for investigating
the pathogenesis of the clinical phenotype in Sialuria patients.
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